Low-Dose radiation plus immunotherapy shows promise for Tough-to-Treat nasopharyngeal cancer

NCT ID NCT07325539

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing whether adding low-dose radiotherapy to a standard chemotherapy regimen (gemcitabine and cisplatin) plus the immunotherapy drug toripalimab can help control recurrent or metastatic nasopharyngeal carcinoma. About 55 adults aged 18-65 with confirmed non-keratinizing NPC will receive up to 6 cycles of the combination, followed by maintenance toripalimab. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab, gemcitabine, cisplatin, and low-dose radiotherapy
What this could lead to: If successful, this combination could offer a new treatment option for people with nasopharyngeal cancer that has come back or spread.
What could go wrong: This is an early Phase 2 trial with only 55 people, no comparison group, and side effects from chemotherapy and immunotherapy can be serious. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARANGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARANGEAL CANCER NASOPHARYNGEAL CANCINOMA (NPC)

Contacts and locations

Locations

Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Shenzhen, Guangdong, 518116, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.